AARD EFFECT SEC Filing Analysis

Latest settled — T+20d

AARD ▲ +27.60% at T+20d

SHORT call ✗ call lost -27.60% · α vs SPY -18.62% · entry $4.13 → $5.27

Next anchor: T+60d in 5w

Last close $4.54 (close May 22) · -9.93% from $4.13 entry (call sign-flipped)

Entry anchored
Apr 2, 03:59 PM ET
via Databento tick

T+1d

-2.18%

call +2.18% · α +2.24%

$4.04

settled 7w ago

T+5d

-2.91%

call +2.91% · α +7.04%

$4.01

settled 6w ago

T+20d

+27.60%

call -27.60% · α -18.62%

$5.27

settled 20d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Aardvark Therapeutics' S-3 shelf registration has become effective, allowing the company to raise up to $400 million through various securities offerings, including a $150 million ATM program. This follows recent clinical trial pauses and signals potential near-term dilution risk.

Actionable Insight

Traders should monitor for imminent share issuance, particularly through the ATM program, which could lead to significant downward price pressure. The combination of clinical setbacks and newly available capital-raising ability increases near-term downside risk.

Key Facts

S-3 shelf registration (File No. 333-294537) became effective on 2026-04-03
Shelf allows issuance of up to $400 million in securities, including a $150 million ATM with Piper Sandler
Company recently paused key clinical trials due to safety concerns
Market cap is $94 million, making potential offerings highly dilutive

Financial Impact

Up to $400 million in potential equity issuance against a $94 million market cap, with $150 million available immediately via ATM

dilutionequitymarket cap

Risk Factors

Significant shareholder dilution from potential equity offerings
Downward pressure on stock price from ATM share sales
Continued clinical development risks following trial pauses

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
EFFECT Filing (Primary)	9999999995-26-001083
Document: 9999999995-26-001083-index.html	9999999995-26-001083
Document: 9999999995-26-001083.txt	9999999995-26-001083

7 reports for AARD

T+1T+5T+20T+60

100% Hit rate 4 of 4 directional calls best @ T+1▲ +6.10%Mar 23, 2026

Filters

Reports for AARD — sortable, filterable
	Type				Now
May 14, 2026 9d ago	Press Release BEARISH ★ 8/10	$6.75 awaiting T+5	awaiting T+5	—	$4.54 (+32.74%)
May 7, 2026 16d ago	8-K BEARISH ★ 6/10	$5.60 $6.59	▼ −17.68%	▼ −16.17%	$4.54 (+18.93%)
Apr 6, 2026 6w ago	EFFECT BEARISH ★ 7/10	$4.13 $4.01	▲ +2.91%	▲ +7.04%	$4.54 (−9.93%)
Apr 3, 2026 7w ago	424B5 BEARISH ★ 7/10	$4.13 $4.01	▲ +2.91%	▲ +7.04%	$4.54 (−9.93%)
Mar 24, 2026 8w ago	8-K NEUTRAL ★ 4/10	$3.77 $3.77	· 0.00%	▲ +0.42%	$4.54 (+20.42%)
Mar 23, 2026 8w ago	S-3 BEARISH ★ 7/10	$3.77 $3.77	· 0.00%	▼ −0.42%	$4.54 (−20.42%)
Mar 23, 2026 8w ago	Press Release BEARISH ★ 8/10	$3.77 $3.77	· 0.00%	▼ −0.42%	$4.54 (−20.42%)

US Market Status

Market Closed — Opens Tue (35h 13m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access